CHAVI’s Mission:
CHAVI’s Mission Find the enabling technology to make a preventive HIV vaccine
How will CHAVI do this?:
How will CHAVI do this? By studying the very earliest stages of HIV infection and to elucidate the correlates of protective immunity in individuals that initially control HIV viral load
CHAVI and MTCT:
CHAVI and MTCT Identify and prioritize critical unanswered questions relative to MTCT
What are the available assays for studying mucosal samples?
CHAVI is also interested in eventually facilitating the development of a pediatric HIV vaccine
Slide5:
Session 1: MTCT of HIV, background, critical issues, and unanswered questions – Chair: Lynne Mofenson
MTCT, an overview of unanswered questions - Lynne Mofenson
Immunology of MTCT: what is known of correlates of immunity in transmission intrapartum and post partum - Katherine Luzuriaga
Animal models of MTCT in breastfeeding: what have they taught us? - Marta Marthas
Antibody protection of MTCT, prospects for prevention - Ruth Ruprecht
CHAVI/IMPAACT Interactions:
CHAVI/IMPAACT Interactions
IMPAACT Lab Committee Business Meeting:
IMPAACT Lab Committee Business Meeting Lab Committee Vice Chair
Budget issues - Brandy Price
De-funded sites - specimens
Progress reports – due Feb 28th
IMPAACT/PTN/MTN joint meeting - ~March 25-31
Lab plenary session
GCLP training March 30 and 31
Slide10:
International lab representation
PBMC issues
Training – isolation and freezing
Storing - -80 vs liquid nitrogen
Shipping – dry ice vs dry shippers
Lab structure – how is it working?
Conference calls
Scientific chair representation on Lab Steering